0000000000615387

AUTHOR

Alessio Gambardella

showing 2 related works from this author

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection

2022

Background and Objective Biologics for psoriasis, especially anti-tumor necrosis factor-alpha therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as well in inactive carriers or patients with occult infection. However, some biologics, including anti-interleukin-17 therapies such as secukinumab, seem to be less likely to cause hepatitis reactivation. This study assessed the safety of secukinumab treatment in patients with psoriasis with HBV or HBC infection. Methods This was a retrospective cohort study of patients with moderate-to-severe psoriasis treated with secukinumab at seven Italian centers. Patients serologically positive for one or more of the fo…

Hepatitis B virusSecukinumab.HepacivirusAntibodies Monoclonal HumanizedAntiviral AgentsAntibodiesHepatitis B ChronicMonoclonalHumansPsoriasisPharmacology (medical)ViralChronicHumanizedRetrospective StudiesPsoriasiBiological ProductsHepatitis B Surface AntigensHepatitis ReactivationGeneral MedicineDNAAntibodies Monoclonal Humanized; Antiviral Agents; DNA Viral; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; RNA; Retrospective Studies; Virus Activation; Biological Products; Hepatitis B; Hepatitis B Chronic; Hepatitis C; Psoriasispsoriasis treatment secukinumab hepatitis B hepatitis CHepatitis BHepatitis CDNA ViralRNAVirus Activation
researchProduct

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

2022

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-alpha therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab. Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection. Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline an…

reactivationBiologicpsoriasis.latent tuberculosis infectionsecukinumabchemoprophylaxisDermatologyBiologicsBiologics; chemoprophylaxis; latent tuberculosis infection; psoriasis; reactivation; secukinumab.Antibodies Monoclonal HumanizedSeverity of Illness IndexTreatment OutcomeLatent TuberculosisIsoniazidHumansPsoriasisTuberculosisRifampinchemoprophylaxiRetrospective Studiespsoriasi
researchProduct